Lennie Derde
A5114374894- COVID-19 Clinical Research Studies
- Sepsis Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Nosocomial Infections in ICU
- Antibiotic Resistance in Bacteria
- Respiratory Support and Mechanisms
- Antibiotic Use and Resistance
- Intensive Care Unit Cognitive Disorders
- Pneumonia and Respiratory Infections
- Antimicrobial Resistance in Staphylococcus
- Bacterial Identification and Susceptibility Testing
- Enterobacteriaceae and Cronobacter Research
- COVID-19 and healthcare impacts
- Health Systems, Economic Evaluations, Quality of Life
- Meta-analysis and systematic reviews
- Venous Thromboembolism Diagnosis and Management
- SARS-CoV-2 and COVID-19 Research
- Emergency and Acute Care Studies
- Infection Control and Ventilation
- Hematological disorders and diagnostics
- Thermal Regulation in Medicine
- Statistical Methods in Clinical Trials
- Patient Satisfaction in Healthcare
- Climate Change and Health Impacts
- Infections and bacterial resistance
University Medical Center Utrecht
2014-2025
Utrecht University
2011-2025
Medical Research Institute of New Zealand
2023
University of Auckland
2023
Middlemore Hospital
2023
Auckland City Hospital
2023
Oklahoma State University Center for Health Sciences
2011-2022
University Health Network
2021
St. Michael's Hospital
2021
Health Sciences Centre
2021
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands people around world. Urgent guidance for clinicians caring sickest these patients needed. We formed panel 36 experts from 12 countries. All members completed World Health Organization conflict interest disclosure form. proposed 53 questions that are relevant to management COVID-19 in ICU. searched literature direct and...
The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.We evaluated tocilizumab and sarilumab an ongoing international, multifactorial, adaptive platform trial. Adult Covid-19, within 24 hours after starting organ support the intensive care unit (ICU), were randomly assigned to receive (8 mg per kilogram body weight), (400 mg), or standard (control). primary outcome was respiratory cardiovascular support-free days, on...
Background: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands people around world. Urgent guidance for clinicians caring sickest these patients needed. Methods: We formed panel 36 experts from 12 countries. All members completed World Health Organization conflict interest disclosure form. proposed 53 questions that are relevant to management COVID-19 in ICU. searched...
Thrombosis and inflammation may contribute to morbidity mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill Covid-19.
<h3>Importance</h3> Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. <h3>Objective</h3> To determine whether hydrocortisone improves outcome patients with COVID-19. <h3>Design, Setting, and Participants</h3> An ongoing adaptive platform trial testing multiple interventions within therapeutic domains, example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 June 17, 2020, 614 adult suspected confirmed COVID-19 were enrolled...
Thrombosis and inflammation may contribute to the risk of death complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation improve outcomes in noncritically ill who are hospitalized Covid-19.In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned were Covid-19 not critically (which was defined as an absence critical care-level organ support at enrollment) receive pragmatically regimens either...
BACKGROUND: The coronavirus disease 2019 pandemic continues to affect millions worldwide. Given the rapidly growing evidence base, we implemented a living guideline model provide guidance on management of patients with severe or critical in ICU. METHODS: Surviving Sepsis Campaign Coronavirus Disease panel has expanded include 43 experts from 14 countries; all members completed an electronic conflict-of-interest disclosure form. In this update, addressed nine questions relevant managing We...
Intensive care units (ICUs) are high-risk areas for transmission of antimicrobial-resistant bacteria, but no controlled study has tested the effect rapid screening and isolation carriers on in settings with best-standard precautions. We assessed interventions to reduce colonisation bacteria European ICUs.We did this three phases at 13 ICUs. After a 6 month baseline period (phase 1), we an interrupted time series universal chlorhexidine body-washing combined hand hygiene improvement months...
There is broad interest in improved methods to generate robust evidence regarding best practice, especially settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale design of a large, international trial that combines features adaptive platform trials with pragmatic point-of-care determine treatment strategies for patients admitted an intensive care unit severe community-acquired pneumonia. The uses novel design, entitled...
Abstract Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and sarilumab an ongoing international, multifactorial, adaptive platform trial. Adult Covid-19, within 24 hours commencing organ support intensive care unit, were randomized to receive either (8mg/kg) or (400mg) standard (control). primary outcome was ordinal scale combining in-hospital mortality (assigned −1)...
Severe community-acquired pneumonia (sCAP) is associated with high morbidity and mortality, while European non-European guidelines are available for pneumonia, there no specific sCAP.The Respiratory Society (ERS), of Intensive Care Medicine (ESICM), Clinical Microbiology Infectious Diseases (ESCMID) Latin American Thoracic Association (ALAT) launched a task force to develop the first international sCAP. The panel comprised total 18 four experts, as well two methodologists. Eight clinical...
Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity treatment effect (HTE) across individuals. Better understanding HTE could facilitate individualized decision-making. Objective To evaluate for and compare approaches assessing HTE. Design, Setting, Participants Exploratory analysis a multiplatform adaptive RCT vs usual care pharmacologic thromboprophylaxis 3320 enrolled...
To perform the first multinational Enterobacter cloacae clonality study, using MLST scheme newly developed in Japan.The analysis included 195 rectal carriage E. isolates resistant to expanded-spectrum cephalosporins (ESCs), collected from patients 12 hospital units across Europe and Israel. All of were typed by PFGE 173 subjected MLST. ESC resistance was analysed phenotypically; genes encoding ESBLs carbapenemases identified PCR sequencing.MLST distinguished 88 STs, which correlated with...